Banks Turner, MD
Family Medicine · Richmond, VANPI 1487633731
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 36.6% of the total. Reporting peaked in 2023 at $457 and has fallen 69.4% since, to $140 in 2025.
Across 85 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$499
- Amgen$130
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$127
- Pfizer$119
- Abbott$94
- Novartis$67
- plus $328 from 15 others
Across 19 payments — averaging $3816.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Swedish Orphan Biovitrum AB$42K
- AstraZeneca$30K
What the payments were for
- Food & beverage$1,34799%
- Entertainment$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $499 |
| Amgen | 8 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $127 |
| Pfizer | 7 | $119 |
| Abbott | 4 | $94 |
| Novartis | 5 | $67 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Dexcom, Inc. | 2 | $36 |
| Bausch Health US, LLC | 2 | $34 |
| Lilly USA, LLC | 2 | $32 |
| Medtronic | 1 | $30 |
| Tris Pharma Inc | 1 | $21 |
| Gilead | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| Optos, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| GSK | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
$1,364 in reported general payments places this provider in the 70th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 183 | $171,164 |
| XareltoRivaroxaban | 70 | $49,049 |
| OzempicSemaglutide | 40 | $43,744 |
| JardianceEmpagliflozin | 36 | $38,429 |
| JanuviaSitagliptin Phosphate | 30 | $36,821 |
| TrulicityDulaglutide | 24 | $29,823 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $24,966 |
| MounjaroTirzepatide | 18 | $24,648 |
| MyrbetriqMirabegron | 36 | $18,650 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $8,087 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $7,350 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $6,470 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,506 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,476 |
| SynthroidLevothyroxine Sodium | 70 | $5,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $119 | $172,593230 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $32 | $54,47242 claims |
| Johnson & JohnsonXarelto | $12 | $49,04970 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $19 | $45,77948 claims |
| Novo NordiskOzempic | $17 | $43,74440 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $13 | $30,47147 claims |
| AbbVieSynthroid | $499 | $5,19270 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Richmond
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- James FosterRichmond$27K
- Daniel DavidRichmond$16K
- Douglas KlassettRichmond$16K
- James ZelenakRichmond$15K
- David SteinRichmond$15K
- Richard TateRichmond$14K
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.